15-11-2024, 13:00

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
Globe Newswire15-11-2024, 13:00
22-10-2024, 18:00

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Globe Newswire22-10-2024, 18:00
8-10-2024, 18:00

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
Globe Newswire8-10-2024, 18:00
22-05-2024, 12:00

Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Globe Newswire22-05-2024, 12:00
30-04-2024, 12:00

Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
Globe Newswire30-04-2024, 12:00
22-04-2024, 12:00

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
Globe Newswire22-04-2024, 12:00
31-01-2024, 13:00

Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
Globe Newswire31-01-2024, 13:00
22-01-2024, 13:00

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
Globe Newswire22-01-2024, 13:00